Search results
Results From The WOW.Com Content Network
There was good news to share, but the market focused on a declining sales forecast and hammered the stock lower. Last November, Moderna said it expected 2024 revenue to land in a range between $3 ...
Moderna stock fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US, which put ...
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. Despite what it seems, though, Moderna has made clinical and regulatory progress. Let's find out whether this ...
Moderna (MRNA) began trading on the S&P 500 on Wednesday, and the stock rose 4.48% in its debut.
But Moderna's news hasn't been as bright recently. Last month, the company revised coronavirus vaccine revenue downward due to lower sales. And in its update this week, the biotech made ...
Vaccine maker Moderna (MRNA) is on everyone’s radar, with shares rocketing from the $20 level in January to over $60 today. Moderna stock got another small boost yesterday after the inventor of ...
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...